IOBTQ.US IO Biotech, Inc.

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 15, 2026
Market cap
USD 7.19K
P/E
-
P/B
0.01x
ROE
-8,344.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.

Is IOBTQ.US undervalued?

Graham number

The Graham number of IO Biotech, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IO Biotech, Inc. fundamental analysis

No fundamental analysis for IO Biotech, Inc. yet.

IO Biotech, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase…

Full company profile